TY - JOUR AU - Claudia Burz AU - Ben Aziz AU - Loredana Bălăcescu AU - Luminiţa Leluţiu AU - Rareş Buiga AU - Gabriel Samasca AU - Alexandru Irimie AU - Cosmin Lisencu PY - 2016/07/31 Y2 - 2024/03/29 TI - TUMOR MARKERS USED IN MONITORING THE TUMOR RECURRENCE IN PATIENTS WITH COLORECTAL CANCER JF - Medicine and Pharmacy Reports JA - Medicine and Pharmacy Reports VL - 89 IS - 3 SE - Original Research DO - 10.15386/cjmed-635 UR - https://medpharmareports.com/index.php/mpr/article/view/635 AB - Background and aims. The aim of this study was to investigate the value of serum carcinoembryonic antigen (CEA) and carbohydrate antigen (CA 19-9) correlated with some tissue molecules as predictive markers for recurrence in colon cancer.Methods. A total of 30 patients diagnosed with colon cancer stage II or III who underwent optimal surgery were enrolled in study. Tumor markers CEA and CA 19-9 were determined before surgery. Tumor samples were prepared using tissue microarray kit (TMA) then stained for different cellular markers (Ki 67, HER2, BCL2, CD56, CD4, CD8) and analyzed using Inforatio programme for quantitative determination. All patients received standard adjuvant treatment, which consisted of eight cycles chemotherapy type XELOX. The patients were followed up for 3 years.Results. Upon 3 years follow-up, 67% of patients developed tumor relapse, the most common site of metastasis being the liver. No correlations were observed between either serum or tissue tumor markers and the risk of tumor relapse.Conclusion. Over 50% of patients with colon cancer who had optimal treatment developed metastasis. No statistically significant predictive value for investigated molecules was found. Future studies are needed to confirm the use of molecular markers in monitoring patients with colorectal cancer ER -